

COMPANY OVERVIEW

Aurinia is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerular sclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).

RECENT NEWS

Aurinia Establishes At-the-Market Facility

Sep 13 2019, 5:11 PM EDT

STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	605.16m
Last Price	\$6.59
52-Week Range	\$5.06 - \$7.85

09/13/2019 04:00 PM EDT

INVESTOR RELATIONS

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications
and Investor Relations
IR@auriniapharma.com

MANAGEMENT TEAM

Peter Greenleaf, MBA
Chief Executive Officer, Director

Neil Solomons, M.D.
Chief Medical Officer

Michael Martin
Chief Operating Officer

Dennis Bourgeault
Chief Financial Officer

Robert Huizinga, Ph.D., R.N., CNeph(C)
Executive Vice President, Corporate Development

Max Donley, MBA
Executive Vice President, Internal Operations and
Strategy

Erik Eglite, D.P.M., J.D., M.B.A.
Senior Vice President, General Counsel & Chief
Corporate Compliance Officer

Rashieda Gluck
Senior Vice President, Global Clinical Operations

Simrat Randhawa, M.D., M.B.A.
Senior Vice President, Clinical & Medical Affairs

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and
Investor Relations

Ron Demers
Vice President, Manufacturing and Supply Chain

Lawrence (Larry) D. Mandt
Vice President, Quality & Regulatory Affairs

Bradley J. Dickerson
General Manager, Americas & Global Commercial Lead

Sue Evans, MBA, RAC
Head, Regulatory Affairs

AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Canada

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.